Volume | 505,975 |
|
|||||
News | - | ||||||
Day High | 0.102 | Low High |
|||||
Day Low | 0.098 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Heart Test Laboratories Inc | HSCS | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
0.0995 | 0.098 | 0.102 | 0.09995 | 0.0999 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
690 | 505,975 | $ 0.1001489 | $ 50,673 | - | 0.0905 - 1.32 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
16:13:53 | 57 | $ 0.101 | USD |
Heart Test Laboratories Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
6.56M | 65.56M | - | 5k | -6.35M | -0.10 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Heart Test Laboratories News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical HSCS Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.1017 | 0.11 | 0.0905 | 0.1027799 | 937,669 | -0.00175 | -1.72% |
1 Month | 0.123 | 0.123 | 0.0905 | 0.1082654 | 983,230 | -0.02305 | -18.74% |
3 Months | 0.135 | 0.185 | 0.0905 | 0.131356 | 1,424,695 | -0.03505 | -25.96% |
6 Months | 0.39 | 0.52 | 0.0905 | 0.1868322 | 5,749,152 | -0.29005 | -74.37% |
1 Year | 1.03 | 1.32 | 0.0905 | 0.1956469 | 2,905,454 | -0.93005 | -90.30% |
3 Years | 3.75 | 6.00 | 0.0905 | 0.8641899 | 2,099,103 | -3.65 | -97.33% |
5 Years | 3.75 | 6.00 | 0.0905 | 0.8641899 | 2,099,103 | -3.65 | -97.33% |
Heart Test Laboratories Description
Heart Test Laboratories Inc is a medical technology company focused on applying innovative AI-based technology to an ECG to expand and improve an ECG's clinical usefulness. The objective of the company is to make an ECG a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. |